<DOC>
	<DOCNO>NCT00511849</DOCNO>
	<brief_summary>The purpose study test SU011248 ( sunitinib ) combination paclitaxel/carboplatin . This combination regimen test safety antitumor activity .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically proven diagnosis advance solid malignancy amenable treatment curative intent Candidates treatment carboplatin paclitaxel maximum 2 prior chemotherapy regimen ECOG performance status 0 1 Prior chemotherapy , radiation therapy surgery within 4 week prior study entry except palliative radiotherapy nontarget , metastatic lesion Diagnosis second malignancy within past 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>